Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEWSOL-5 is a hypertonic ophthalmic solution developed and marketed by Martia Laboratories, primarily used for the treatment of ocular edema, specifically corneal edema. The formulation contains 5% sodium chloride, which acts as an osmotic agent. When applied topically to the eye, it increases the tonicity of the tear film, creating an osmotic gradient that draws excess fluid out of the edematous corneal tissue. This reduction in swelling helps to improve visual clarity and relieve discomfort associated with corneal hydration. It is a marketed product, particularly in the Indian ophthalmic care sector.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DEWSOL-5.